Law360 (October 9, 2018, 1:22 PM EDT) -- Boehringer Ingelheim Pharmaceuticals has won its third straight bellwether trial over the alleged bleeding risk of its blood thinner Pradaxa, after a Connecticut state jury rejected a man's claims that the drug caused a life-threatening bout of internal bleeding.
The Hartford jury returned on Friday shortly after 3 p.m., after starting deliberations at 10 a.m., with a verdict fully in favor of the pharmaceutical company following the nearly three-week trial, rejecting plaintiff William Bedsole's claims that Boehringer had failed to properly study its drug and failed to provide consumers with adequate warnings about it.
Boehringer released a statement on Friday touting...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!